Financial Performance - The company's revenue for the six months ended September 30, 2023, was approximately HKD 93,373,000, an increase of about 3.58% compared to HKD 90,146,000 for the same period in 2022, driven by growth in the hemodialysis business[6]. - The operating loss attributable to the company's owners for the period was approximately HKD 3,050,000, compared to a loss of HKD 2,506,000 in 2022[6]. - Basic and diluted loss per share was approximately HKD 0.54, compared to HKD 0.45 in 2022[8]. - The total comprehensive loss for the period was approximately HKD 7,418,000, compared to HKD 13,425,000 in 2022[8]. - The company reported a loss of HKD (3,050,000) for the period ended April 1, 2023, compared to a loss of HKD (2,506,000) for the previous period[12]. - The group recorded a loss attributable to the owners of the company of approximately HKD 3,050,000 for the period, compared to a loss of approximately HKD 2,506,000 in the same period in 2022[71]. Cash and Liquidity - Total cash and cash equivalents as of September 30, 2023, were approximately HKD 15,765,000, up from HKD 9,876,000 as of March 31, 2023[6]. - The net cash generated from operating activities for the six months ended September 30, 2023, was HKD 10,056,000, a decrease of 27.5% compared to HKD 13,905,000 in the same period of 2022[21]. - The net cash used in investing activities for the six months ended September 30, 2023, was HKD (254,000), an improvement from HKD (442,000) in the previous year[21]. - The net cash generated from financing activities for the six months ended September 30, 2023, was HKD 1,384,000, down from HKD 4,079,000 in the same period of 2022[21]. - The cash and cash equivalents increased to HKD 15,765,000 as of September 30, 2023, compared to HKD 13,204,000 at the same time last year[21]. - The current ratio as of September 30, 2023, was approximately 1.72, down from approximately 2.02 as of March 31, 2023, indicating a decrease in liquidity[75]. Assets and Liabilities - The company's total assets as of September 30, 2023, were approximately HKD 175,272,000, compared to HKD 173,448,000 as of March 31, 2023[10]. - Current liabilities increased to approximately HKD 49,143,000 as of September 30, 2023, from HKD 35,236,000 as of March 31, 2023[11]. - Non-current assets decreased to approximately HKD 90,747,000 as of September 30, 2023, from HKD 96,579,000 as of March 31, 2023[10]. - The company's total liabilities as of September 30, 2023, were not explicitly stated but can be inferred from the equity and cash flow data presented[12]. - Total liabilities as of September 30, 2023, were HKD 62,287,000, with HKD 53,905,000 classified under pharmaceutical wholesale and dialysis services[37]. Revenue Breakdown - Total revenue for the six months ended September 30, 2023, was HKD 93,373,000, with HKD 25,139,000 from pharmaceutical wholesale and distribution, and HKD 68,234,000 from dialysis treatment and consulting services[32]. - Revenue from the wholesale business was approximately HKD 25,139,000, a decrease of about 8.78% compared to HKD 27,560,000 in 2022[55]. - Revenue from the blood dialysis business increased to approximately HKD 68,234,000, representing a growth of about 9.02% from HKD 62,586,000 in 2022[56]. - The company recorded a profit of approximately HKD 2,473,000 from the blood dialysis business, up from HKD 2,089,000 in 2022[56]. - Other income and revenue for the period was approximately HKD 3,011,000, an increase of about HKD 2,752,000 compared to the same period in 2022, mainly from the sale of a self-operated hemodialysis treatment center in Guangdong, China[65]. Expenses - Selling and distribution expenses were approximately HKD 19,791,000, an increase of about HKD 1,792,000 or approximately 9.96% compared to the same period in 2022, mainly due to increased marketing and logistics costs[66]. - Administrative expenses were approximately HKD 11,883,000, an increase of about HKD 1,733,000 or approximately 17.07% compared to the same period in 2022, primarily due to increases in depreciation, travel, and general office expenses[67]. - The company incurred financial expenses of HKD 893,000 for the six months ended September 30, 2023, down from HKD 938,000 in the same period of 2022[40]. - Depreciation of property, plant, and equipment for the period was HKD 4,368,000, compared to HKD 2,761,000 in the previous year[39]. Shareholder Information - As of September 30, 2023, Mr. Wang holds a total equity interest of 168,755,611 shares, representing approximately 30.12% of the issued shares[85]. - The company has a total of 156,862,198 shares held by Wei Yang Investment Development Limited, which accounts for about 28.00% of the issued shares[89]. - The total equity interest of major shareholders, including Expert Wealth Investments Limited and Hong Kong Financial Limited, is also 156,862,198 shares, representing approximately 28.00%[89]. - The shares held by Wei Yang are pledged to Hong Kong Financial Limited, which is wholly owned by Expert Wealth Investments Limited[89]. Corporate Governance - The company has adopted a code of conduct for directors regarding securities trading, which complies with the standard code[97]. - The company has maintained a high level of corporate governance and has fully complied with the corporate governance code during the reporting period[98]. - The company has not established a chairman position since the resignation of the previous chairman in 2014, and the board believes current members can share the responsibilities effectively[98]. - The audit committee has reviewed the group's unaudited condensed consolidated results for the period and believes they have been prepared in accordance with applicable accounting standards[105]. - The interim report has been published on both the Hong Kong Stock Exchange website and the company's website[107].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公佈全部或任何部 分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 WANJIA GROUP HOLDINGS LIMITED 萬 嘉 集 團 控 股 有 限 公司 （於開曼群島註冊成立之有限公司） 401) （股份代號： 截至二零二三年九月三十日止六個月之 中期業績公佈 萬嘉集團控股有限公司（「本公司」）董事會（「董事會」，及董事會成員，「董事」）欣然 公佈本公司及其附屬公司（統稱「本集團」）截至二零二三年九月三十日止六個月（「本 期間」）之未經審核簡明綜合中期業績，連同二零二二年同期之未經審核比較數字。 本集團之本期間中期業績乃未經審核，惟已獲本公司審核委員會（「審核委員會」）審 閱。 財務摘要 • 93,373,000 90,146,000 本期間收益約為 港元（二零二二年：約 港元），較二零 3.58% ...

Financial Performance - The total revenue for the Group for the year was approximately HK$173.702 million, representing an increase of approximately HK$18.879 million compared to 2022[13]. - The gross profit was approximately HK$56.936 million, an increase of approximately HK$2.702 million compared to 2022[13]. - The profit for the year attributable to the owners of the Company was approximately HK$1.820 million, due to the improvement in the hemodialysis treatment and consultancy service business segment in the PRC[13]. - Total revenue for the financial year ended 31 March 2023 was approximately HK$173.702 million, representing an increase of approximately 12.19% compared to HK$154.823 million in 2022[27]. - Gross profit for the same period was approximately HK$56.936 million, an increase of approximately 4.98% from HK$54.234 million in 2022[27]. - Profit for the year attributable to owners of the Company was approximately HK$1.820 million, a significant recovery from a loss of approximately HK$50.999 million in 2022[27]. - Revenue from the hemodialysis treatment and consultancy service business was approximately HK$121.424 million, representing an increase of 17.16% compared to 2022[31]. - Revenue from the pharmaceutical wholesale and distribution business was approximately HK$52.278 million, a slight increase of approximately 2.14% compared to HK$51.183 million in 2022[32]. Business Strategy and Development - The Group will focus on developing the hemodialysis treatment and consultancy service business through organic growth and acquisitions[16]. - The establishment of new self-operated hemodialysis treatment centres is planned to expand operating scale and market penetration[17]. - The Group believes that the demand for hemodialysis treatment services in the PRC market is still far from being met, indicating significant potential for development[18]. - The Group aims to expand its business scale by studying market potential in other cities and regions in the PRC[103]. - The Group is focusing on establishing new self-operated hemodialysis treatment centers and providing consulting services to hospitals[106]. Financial Position and Ratios - The Group's total cash and cash equivalents as of 31 March 2023 were approximately HK$9.876 million, up from approximately HK$5.768 million in 2022[27]. - The current ratio improved to approximately 2.02 as of 31 March 2023, compared to approximately 1.79 in 2022[65]. - The gearing ratio decreased to approximately 0.13 as of 31 March 2023, down from approximately 0.15 in 2022[66]. - The Group recorded a reversal of allowance for expected credit losses on trade and other receivables of approximately HK$7.499 million for the year ended 31 March 2023[68]. Employee and Workforce Information - As of March 31, 2023, the Group had 202 full-time employees, an increase from 184 in 2022[88]. - Staff costs for the year ended March 31, 2023, amounted to approximately HK$20.221 million, up from approximately HK$19.247 million in 2022, reflecting a year-on-year increase of about 5.06%[89]. - The gender distribution of employees shows 52 males and 150 females, indicating a higher female representation[199]. - The age group distribution reveals 97 employees are below 30 years old, while 5 employees are above 60 years old, reflecting a younger workforce[199]. - The Group's workforce is primarily located in Mainland China, with 192 employees, while 10 are based in Hong Kong[199]. Governance and Compliance - The Group's compliance team is responsible for interpreting and promoting external regulatory requirements to mitigate market risks[79]. - The Group maintains a zero-tolerance approach towards bribery, extortion, fraud, and money laundering[136]. - The Group's governance structure regularly reviews and monitors corporate management policies and practices[136]. - The Board is responsible for overseeing the Group's ESG risk management and setting related targets[129]. - The Group provided anti-corruption training to directors and staff during the Reporting Period to enhance integrity awareness[140]. Environmental, Social, and Governance (ESG) Initiatives - The Group collaborated with a sustainability consultant to identify environmental, social, and governance risks, focusing on climate change and product safety[104]. - The Group is committed to integrating ESG concepts into business development and has identified key sustainability issues such as climate change and product safety[106]. - The Group identified 8 material ESG issues during the Reporting Period, including Wastewater Management, Combatting Climate Change, and Anti-Corruption[158]. - The Group's environmental and social KPIs are disclosed in compliance with the "Comply or Explain" provisions of the Listing Rules[114]. - The Group's whistleblowing policy allows employees to report suspected violations to management[139]. Customer Satisfaction and Quality Control - The Group received no complaints related to products and services during the reporting period, indicating high customer satisfaction[188]. - The Group has established a customer complaint management system to continually improve service quality[187]. - The Group emphasizes drug safety and effectiveness, implementing effective quality control measures throughout procurement, storage, sales, and transportation processes[163]. - The Group's Quality Management Department is responsible for ensuring consistent quality throughout the supply chain and conducts regular internal reviews and risk assessments[179]. - No sold or shipped products were recalled for safety and health reasons during the Reporting Period[180].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公佈全部或任何部 分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 WANJIA GROUP HOLDINGS LIMITED 萬 嘉 集 團 控 股 有 限 公司 （於開曼群島註冊成立之有限公司） 401) （股份代號： 截至二零二三年三月三十一日止年度之 全年業績公佈 財務摘要 本集團截至二零二三年三月三十一日止財政年度之業績概要如下： • 173,702,000 154,823,000 總收益約為 港元（二零二二年：約 港元），較二零二二 12.19% 年增加約 。 • 56,936,000 54,234,000 毛利約為 港元（二零二二年：約 港元），較二零二二年增 4.98% 加約 。 • 4,473,000 47,383,000 營運業務溢利約為 港元（二零二二年：營運業務虧損約 港 元）。 ...

Financial Performance - The company's revenue for the period was approximately HKD 90,146,000, an increase of about 28.27% compared to HKD 70,281,000 in the same period last year, driven by growth in the hemodialysis business[6] - The company reported an operating loss of approximately HKD 2,506,000 for the period, compared to a profit of HKD 414,000 in the previous year[6] - Basic and diluted loss per share was approximately HKD 0.45, compared to earnings of HKD 0.07 per share in the previous year[8] - The company experienced a comprehensive loss of HKD 13,425,000 for the period, compared to a comprehensive income of HKD 4,003,000 in the previous year[8] - The company reported a net cash inflow from operating activities of HKD 13,905,000 for the six months ended September 30, 2022, compared to a net outflow of HKD 9,504,000 for the same period in 2021[23] - The total comprehensive loss for the period was HKD 13,425,000, which included a loss of HKD 2,506,000 and other comprehensive losses of HKD 10,917,000[17] - The group reported a net loss attributable to shareholders of approximately HKD 2,506,000, compared to a profit of approximately HKD 414,000 in the previous year[70] Assets and Liabilities - The total assets of the company as of September 30, 2022, were approximately HKD 179,252,000, down from HKD 191,818,000 as of March 31, 2022[10] - Non-current assets decreased from HKD 110,365,000 to HKD 97,829,000 during the same period[10] - Current liabilities increased to HKD 49,101,000 from HKD 45,468,000, with trade and other payables being HKD 28,844,000[11] - The company's equity attributable to owners decreased from HKD 126,179,000 to HKD 112,757,000[10] - The total liabilities of the group as of September 30, 2022, were HKD 64,580,000, compared to HKD 63,722,000 as of March 31, 2022, showing a slight increase[38] Cash Flow - Total cash and cash equivalents as of September 30, 2022, were approximately HKD 13,204,000, up from HKD 5,768,000 as of March 31, 2022[6] - The cash and cash equivalents increased by HKD 17,542,000 during the six months ended September 30, 2022, compared to a decrease of HKD 16,158,000 in the same period of the previous year[23] - The company had a financing cash inflow of HKD 4,079,000 for the six months ended September 30, 2022, compared to an outflow of HKD 1,452,000 in the previous year[23] - The company’s accumulated losses as of September 30, 2022, stood at HKD 867,246,000, an increase from HKD 864,740,000 on April 1, 2022[17] Revenue Segments - The group operates in two main segments: pharmaceutical wholesale and distribution, and hemodialysis treatment and consulting services, with revenues of HKD 27,560,000 and HKD 62,586,000 respectively for the current period[33] - Revenue from the pharmaceutical wholesale and distribution business was approximately HKD 27,560,000, an increase of about 6.43% from HKD 25,895,000 in the previous year[55] - Revenue from the hemodialysis treatment and consulting services business increased by approximately 41%, reaching HKD 62,586,000 compared to HKD 44,386,000 in the previous year[57] - Revenue from the blood dialysis business was approximately HKD 62,586,000, representing an increase of about HKD 18,200,000 or approximately 41% year-on-year, driven by an increase in the number of patients treated[62] Expenses and Costs - Selling and distribution expenses increased by approximately HKD 4,544,000 or about 33.77% to approximately HKD 17,999,000, primarily due to increased marketing and logistics costs[66] - The financial expenses for the six months ended September 30, 2022, were HKD 938,000, up from HKD 662,000 in the same period of 2021, reflecting increased borrowing costs[40] - The group’s employee costs, including director remuneration, increased to HKD 16,810,000 for the six months ended September 30, 2022, compared to HKD 10,495,000 in the same period of 2021, representing a rise of 60.1%[39] Corporate Governance - The company has maintained a high level of corporate governance and has fully complied with the corporate governance code during the reporting period[105] - The Remuneration Committee, established on September 24, 2013, includes one executive director and three independent non-executive directors, responsible for determining the remuneration packages of all executive directors[107] - The Nomination and Corporate Governance Committee, also established on September 24, 2013, is tasked with reviewing the board's structure and recommending changes as necessary[108] - The Audit Committee, formed on September 24, 2013, oversees the integrity of the company's financial statements and the effectiveness of internal controls[110] Shareholder Information - As of September 30, 2022, Mr. Wang holds a total equity interest of 163,155,611 shares, representing approximately 29.12% of the issued shares[90] - The company’s major shareholder, Weiyang Investment Development Limited, holds 156,862,198 shares, accounting for approximately 28.00% of the total issued shares[95] - The total number of unexercised share options granted to directors and employees amounts to 30,473,892 shares, which is approximately 5.43% of the total issued shares[97] - Employees were granted a total of 14,570,000 share options, representing approximately 2.60% of the total issued shares[97] Operational Changes - The company terminated operations at the blood dialysis treatment center in Xianyou, Fujian, due to the inability of Xianyou Boai Hospital to pay its share of profits, resulting in a legal claim for approximately RMB 3,564,000[84] - The management agreement with Zhuhai Kowloon Hospital was terminated, with the hospital agreeing to refund a deposit of RMB 11,000,000 within three months[87] - The company has received all 31 blood dialysis machines back from Xianyou Boai Hospital, indicating no further operational collaboration[85] - The company is in the process of negotiating an early termination agreement with Xianyou Boai Hospital upon receipt of all outstanding payments[85]

Financial Performance - Total revenue for the year ended 31 March 2022 was approximately HK$154.823 million, an increase of approximately HK$40.737 million compared to 2021[15]. - Gross profit for the year was approximately HK$54.234 million, representing an increase of approximately HK$12.898 million compared to 2021[15]. - Loss attributable to the owners of the Company for the year was approximately HK$50.999 million, primarily due to an impairment loss on goodwill of approximately HK$46.630 million[15]. - Revenue from hemodialysis treatment and consultancy service business was approximately HK$103.640 million, a significant increase of 87.36% compared to 2021[19]. - Revenue from pharmaceutical wholesale and distribution business was approximately HK$51.183 million, representing a decrease of approximately 12.91% compared to 2021[20]. - Total revenue for the year ended March 31, 2022, was approximately HK$154.823 million, representing an increase of approximately 35.71% compared to 2021[34]. - Gross profit for the year was approximately HK$54.234 million, an increase of approximately 31.20% over 2021[34]. - The loss for the year attributable to owners of the Company was approximately HK$50.999 million, primarily due to an impairment loss on goodwill of approximately HK$46.630 million[34]. - The basic and diluted loss per share was approximately HK$9.10 cents, compared to approximately HK$0.81 cents in 2021[34]. - The Group had total cash and cash equivalents of approximately HK$5.768 million as of March 31, 2022, down from approximately HK$25.099 million in 2021[34]. Business Strategy and Development - The Group plans to centralize resources in developing the hemodialysis treatment and consultancy service business through organic growth and acquisitions[21]. - The establishment of new self-operated hemodialysis treatment centers is a key focus for expanding operating scale and market penetration[22]. - The Group believes there is significant unmet demand for hemodialysis treatment services in the PRC market, indicating strong potential for future growth[23]. - The Group plans to focus resources on developing the hemodialysis treatment and consultancy service business through organic growth and acquisitions[25]. - The Group aims to establish new self-operated hemodialysis treatment centers in China to expand operational scale and market penetration[25]. - The Group plans to open six self-operated or joint-venture hemodialysis treatment centers by the end of the fiscal year 2022, with three already opened as of the report date[89]. - The Group's business plan remains unchanged, but delays in opening new centers are being addressed, with alternative locations being considered if delays persist[87]. - Future plans include establishing new self-operated hemodialysis treatment centers and providing consulting services to hospitals[133]. Operational Challenges - Ongoing COVID-19 challenges may continue to create uncertainties in the Group's operating environment, particularly in Guangdong and Fujian Provinces[38]. - Losses were exacerbated by increased costs of sales and services due to COVID-19 restrictions impacting overall profitability in pharmaceutical distribution and hemodialysis services[64]. - The Group's hemodialysis center in Huidong has faced delays in obtaining a specialized license, which is expected to take longer due to the COVID-19 pandemic, with enrollment anticipated in Q2 or Q3 of 2023[72]. - The Huidong Center's operations have been delayed due to the COVID-19 pandemic, with the expected professional license acquisition pushed to Q2 or Q3 of 2023, which was originally anticipated to take 2.5 to 3 years[74][81]. - The Maoming Center's business plan has been significantly delayed due to strong objections from local villagers regarding potential sewage pollution, with an expected opening timeline of 2 to 3 years after objections are resolved[77][87]. - The opening of additional centers in Huizhou and Maoming has been delayed due to unforeseen circumstances, including disputes with partners and the impact of COVID-19[90]. - The combined impact of multiple adverse events in the financial year 2022 has led to the consideration of impairment, reflecting the current value in use of the hemodialysis treatment business[82][83]. Financial Position and Ratios - As of March 31, 2022, the Group had total cash and cash equivalents of approximately HK$5.768 million, a decrease from approximately HK$25.099 million in 2021 due to repayment of shareholder and director loans[94]. - Total current assets increased to approximately HK$81.453 million as of March 31, 2022, compared to approximately HK$66.512 million in 2021, while total current liabilities rose to approximately HK$45.468 million from approximately HK$32.916 million[94]. - The current ratio as of March 31, 2022, was approximately 1.79, down from approximately 2.02 in 2021[94]. - The Group's gearing ratio as of March 31, 2022, was approximately 0.15, an increase from approximately 0.07 in 2021[95]. - The Group had no material capital commitments as of March 31, 2022, compared to approximately HK$1.245 million in 2021[103]. - The Group's financial statements were prepared on a going concern basis, indicating sufficient financial resources for ongoing operations in the foreseeable future[98]. Human Resources - The Group employed 184 full-time employees as of March 31, 2022, an increase from 178 in 2021[117]. - For the year ended 31 March 2022, staff costs amounted to approximately HK$19.247 million, a decrease of 5.7% from HK$20.409 million in 2021[118]. Environmental, Social, and Governance (ESG) - The Group is committed to refining its sustainability governance policies and addressing environmental, social, and governance risks[132]. - The reporting period for the Environmental, Social and Governance Report is from 1 April 2021 to 31 March 2022, covering the Group's pharmaceutical and hemodialysis businesses[139]. - The Group conducted an internal materiality assessment to identify key environmental, social, and governance (ESG) issues relevant to stakeholders during the Reporting Period[146]. - The Group's environmental and social KPIs are disclosed quantitatively, following specific reporting guidance[148]. - The Board oversees the Group's ESG risk management and is responsible for setting and managing ESG-related targets[158]. - The Group employs a strict anti-corruption policy and has established a whistleblowing policy to enhance corporate governance[162]. - During the Reporting Period, the Group did not have any legal cases regarding corrupt practices and was not aware of any material non-compliance with relevant laws[168]. - The Group's pharmaceutical wholesale and distribution business strictly complies with laws and regulations stipulated by the State Food and Drug Administration, including the Medicinal Product Administration Law and the Advertising Law of the People's Republic of China[181]. - During the Reporting Period, 8 significant ESG issues were identified, including Wastewater Management, Combating Climate Change, and Anti-Corruption[177]. - The Group has added a new ESG topic "Combating Climate Change" to address its climate change strategy, reflecting the international community's increasing focus on this issue[177]. - The Group engages stakeholders through various communication channels, including annual general meetings and customer feedback forms, to understand their concerns and expectations[170]. Quality Management and Supply Chain - The Group has established an effective quality management system to protect customers' personal information and ensure the quality of after-sale services[183]. - The Group's operational practices emphasize drug safety and effectiveness, with effective quality control measures in place during procurement, storage, sales, and transportation[181]. - The Group's environmental protection efforts include management of air emissions, energy, and waste, with a focus on compliance and sustainability[179]. - The Group actively participates in community activities and charitable donations to enhance community relations and environmental protection awareness[171]. - The Group engaged a total of 58 medicines and consumables suppliers, all located in the PRC, to ensure supply chain stability[185]. - The Group's storage and transportation facilities comply with national regulations, with systems in place to monitor temperature and humidity, ensuring no products were recalled for safety and health reasons during the Reporting Period[196]. - The Quality Management Department conducts regular internal reviews and risk assessments to maintain stable quality throughout the supply chain[194]. - The Group has established long-term relationships with various large and medium-sized pharmaceutical suppliers to diversify and stabilize the supply chain[185]. - All suppliers are reassessed annually to ensure compliance with the Group's requirements, including environmental policies[190]. - The Group has developed a medicines recycling management system to facilitate systematic recycling when necessary[196]. - No material non-compliance with laws and regulations related to health and safety, advertising, and privacy matters was reported during the Reporting Period[184]. - The Group maintains contact with suppliers through various channels to identify collaboration opportunities and ensure product quality[191]. - The Group's mission is to provide pharmaceutical products to the community and distribute medicine for healthcare institutions[185].

| | | | 公司資料 | 2 | | --- | --- | | 簡明綜合損益及其他全面收益表 | 4 | | 簡明綜合財務狀況表 | 6 | | 簡明綜合權益變動表 | 8 | | 簡明綜合現金流量表 | 10 | | 簡明綜合中期財務報表附註 | 11 | | 管理層討論及分析 | 21 | | 其他資料 | 28 | 萬嘉集團控股有限公司 1 二零二一年╱二零二二年中期報告 公司資料 董事會 董事會現任成員如下： 執行董事 Wang Jia Jun先生 （行政總裁） 非執行董事 蕭致信醫生 獨立非執行董事 黃漢傑先生 劉勇平博士 何敏先生 授權代表 Wang Jia Jun先生 譚子健先生 公司秘書 譚子健先生 審核委員會 黃漢傑先生 （主席） 劉勇平博士 何敏先生 薪酬委員會 黃漢傑先生 （主席） 劉勇平博士 何敏先生 Wang Jia Jun先生 提名及企業管治委員會 Wang Jia Jun先生 （主席） 黃漢傑先生 劉勇平博士 何敏先生 註冊辦事處 Second Floor Century Yard, Cricket Square P.O. Box 902 Grand Cayman KY1- ...

Contents 目 錄 2021 REVIEW 二零二一年回顧 | Corporate Information | 2 | | --- | --- | | 公司資料 | | | Management's Statement | 5 | | 管理層報告 | | | Management Discussion and Analysis | 8 | | 管理層討論及分析 | | | GOVERNANCE REPORT | | | 管治報告 | | | Corporate Governance Report | 17 | | 企業管治報告 | | | Biographical Details of Directors and Senior Management | 34 | | 董事及高級管理人員履歷詳情 | | | Report of the Directors | 38 | | 董事會報告 | | | FINANCIAL STATEMENTS | | | 財務報表 | | | Independent Auditors' Report | 58 | | 獨立核數師報告 | | | Consolidated Sta ...

Wanjia Group Holdings Limited 萬嘉集團控股有限公司 (於開曼群島註冊成立的有限公司) 股份代號: 401 2020/2021 中期報告 | 目 錄 | | | | --- | --- | --- | | 公司資料 | 2 | | | 簡明綜合損益及其他全面收益表 | 4 | | | 簡明綜合財務狀況表 | 6 | | | 簡明綜合權益變動表 | 8 | | | 簡明綜合現金流量表 | 9 | | | 簡明綜合中期財務報表附註 | 10 | | | 管理層討論及分析 | 21 | | | 其他資料 | | 28 | 萬嘉集團控股有限公司 1 二零二零年╱二零二一年中期報告 公司資料 董事會 董事會現任成員如下： 執行董事 Wang Jia Jun先生 （行政總裁） 翁嘉麗女士 獨立非執行董事 黃漢傑先生 劉勇平博士 何敏先生 授權代表 Wang Jia Jun先生 譚子健先生 公司秘書 譚子健先生 審核委員會 黃漢傑先生 （主席） 劉勇平博士 何敏先生 薪酬委員會 黃漢傑先生 （主席） 劉勇平博士 何敏先生 Wang Jia Jun先生 提名及企業管治委員會 Wang Jia Ju ...

Contents 目 錄 2020 REVIEW 二零二零年回顧 | Corporate Information | 2 | | --- | --- | | 公司資料 | | | Management's Statement | 5 | | 管理層報告 | | | Management Discussion and Analysis | 8 | | 管理層討論及分析 | | | GOVERNANCE REPORT | | | 管治報告書 | | | Corporate Governance Report | 17 | | 企業管治報告書 | | | Biographical Details of Directors and Senior Management | 34 | | 董事及高級管理人員履歷詳情 | | | Report of the Directors | 39 | | 董事會報告 | | | FINANCIAL STATEMENTS | | | 財務報表 | | | Independent Auditors' Report | 58 | | 獨立核數師報告 | | | Consolidated S ...